Currently, patients with sepsis whose monocytes have decreased HLA-DR expression and/or patients whose LPS-stimulated whole blood response shows decreased TNF-α production are considered good candidates for immuno-stimulatory therapy [4]. Here, TNF is linked to Sepsis.